EGFR and non-small cell lung carcinoma: Because PFKFB3 is upregulated in EGFR-TKI resistant NSCLC, PFK15 exhibits synergistic impact with erlotinib in wild type and EGFR mutant cell lines (Lypova et al., 2019).